Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma

被引：0
|
作者：
Alsina, Maria [1 ]
Fleitas-Kanonnikoff, Tania [2 ]
机构：
[1] Hosp Univ Navarra, Med Oncol Dept, Translat Med Oncol Invest Grp, Navarrabiomed IdiSNA, C-Irunlarrea 3, Pamplona 35008, Spain
[2] Hosp Clin Univ Valencia, Med Oncol Dept, INCLIVA, Valencia, Spain
来源：
MED | 2024年 / 5卷 / 09期
关键词：
CHEMOTHERAPY; PLACEBO;
D O I：
10.1016/j.medj.2024.05.016
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Immunotherapy has revolutionized the treatment landscape of esophageal squamous cell carcinoma. He et al. present the final results of the randomized phase 3 ESCORT-1st trial, confirming positive survival outcomes when adding the anti-PD1 inhibitor camrelizumab to first-line chemotherapy treatment in Chinese patients with esophageal squamous cell cancer.(1)
引用
收藏
页码：1038 / 1040
页数：3
相关论文
共 50 条
  • [31] A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors
    Khaki, Ali Raza
    Li, Ang
    Diamantopoulos, Leonidas N.
    Miller, Natalie J.
    Carril-Ajuria, Lucia
    Castellano, Daniel
    De Kouchkovsky, Ivan
    Koshkin, Vadim
    Park, Joseph
    Alva, Ajjai
    Bilen, Mehmet A.
    Stewart, Tyler
    Santos, Victor
    Agarwal, Neeraj
    Jain, Jayanshu
    Zakharia, Yousef
    Morales-Barrera, Rafael
    Devitt, Michael
    Nelson, Ariel
    Hoimes, Christopher J.
    Shreck, Evan
    Gartrell, Benjamin A.
    Sankin, Alex
    Tripathi, Abhishek
    Zakopoulou, Roubini
    Bamias, Aristotelis
    Rodriguez-Vida, Alejo
    Drakaki, Alexandra
    Liu, Sandy
    Kumar, Vivek
    Lythgoe, Mark P.
    Pinato, David J.
    Murgic, Jure
    Frobe, Ana
    Joshi, Monika
    Velho, Pedro Isaacsson
    Hahn, Noah
    Buznego, Lucia Alonso
    Duran, Ignacio
    Moses, Marcus
    Barata, Pedro
    Galsky, Matthew D.
    Sonpavde, Guru
    Yu, Evan Y.
    Shankaran, Veena
    Lyman, Gary H.
    Grivas, Petros
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (03): : 464 - 472
  • [32] New First-Line Systemic Treatment Options for Metastatic Esophageal Squamous Cell Carcinoma
    Gibson, Michael K.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (5.5): : 579 - 582
  • [33] Efficacy of Checkpoint Inhibitors in Combination with Chemotherapy for First-Line Treatment of Advanced Non-Squamous NSCLC
    Thein, K.
    Jahan, N.
    Sultan, A.
    Swarup, S.
    Tun, A.
    Yendala, R.
    Ball, S.
    Hlaing, P.
    Htut, T.
    Rehman, S.
    D'Cunha, N.
    Hardwicke, F.
    Tijani, L.
    Awasthi, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S472 - S473
  • [34] Tumour infiltrating lymphocytes characterization in advanced nonsmall cell lung cancer with first-line immune checkpoint inhibitors treatment
    Ruivo, L.
    Pinho Fialho, M.
    Baptista, D.
    Filipe, J.
    VIRCHOWS ARCHIV, 2024, 485 : S450 - S450
  • [35] Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma
    Yoon, Harry H.
    Kato, Ken
    Hubner, Richard
    Raymond, Eric
    Tao, Aiyang
    Liu, Sumei
    Qazi, Ibrahim
    Xu, Jian-Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [36] Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
    Xu, Jianming
    Bai, Yuxian
    Xu, Nong
    Li, Enxiao
    Wang, Buhai
    Wang, Jin
    Li, Xiang
    Wang, Xin
    Yuan, Xianglin
    CLINICAL CANCER RESEARCH, 2020, 26 (17) : 4542 - 4550
  • [37] Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review
    Xu, Jianming
    Bai, Yuxian
    Li, Enxiao
    Xu, Nong
    Shi, Danfeng
    Qian, Jing
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (09) : 981 - 998
  • [38] Immune checkpoint inhibitors in the first-line treatment of metastatic small-cell lung cancer
    Knetki-Wroblewska, Magdalena
    Kowalski, Dariusz M.
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2022, 18 (02): : 104 - 114
  • [39] Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer
    Remon, Jordi
    Besse, Benjamin
    CURRENT OPINION IN ONCOLOGY, 2017, 29 (02) : 97 - 104
  • [40] Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma
    Si, Xiaoyan
    Wu, Shafei
    Wang, Hanping
    Zhang, Xiaotong
    Wang, Mengzhao
    Zeng, Xuan
    Zhang, Li
    THORACIC CANCER, 2018, 9 (08) : 1056 - 1061
12345